A Foundation of Clinical Experience.
Linnaeus is a Penn Center for Innovation UPstart company that was founded in 2016 and is based upon discoveries from the Ridky lab at the University of Pennsylvania. We are developing our initial therapies that are supported by a foundation of clinical experience. Being female and having a history of pregnancy are associated with decreased incidence and improved stage specific survival for many cancers, including melanoma, pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colon carcinomas.
See our video here.
Applied Knowledge
We believe that if you observe the clinical experience and listen to what it tells us, it will lead to the identification of new therapeutic targets for cancer.
Diverse Team
We have assembled a management and development team with complementary skill sets and differing areas of domain expertise that should allow us to get our drug-candidates into humans as safely and as quickly as possible.
Latest News
Company & industry updates from the Linnaeus team
Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Cutaneous Melanoma
Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Cutaneous Melanoma Haddonfield NJ, January 19, 2023--Linnaeus Therapeutics, Inc. (Linnaeus), a privately [...]
Linnaeus Therapeutics Announces Issuance of Patent for LNS8801 by the U.S. Patent and Trademark Office
Linnaeus Therapeutics Announces Issuance of Patent for LNS8801 by the U.S. Patent and Trademark Office Haddonfield NJ, September 21, 2022 - Linnaeus Therapeutics, Inc. (Linnaeus), a [...]
Linnaeus Therapeutics Announces Presentation of LNS8801 Clinical Data at 2022 ESMO Annual Meeting
Linnaeus Therapeutics Announces Presentation of LNS8801 Clinical Data at 2022 ESMO Annual Meeting Haddonfield NJ, September 12, 2022 - Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage [...]
We Listen to the Clinical Experience
We allow it to inform the science that drives the development of new treatments to treat cancer.